Navigation Links
YM BioSciences Closes Public Offering of Common Shares
Date:12/17/2010

r of JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent vascular disrupting agent (VDA).

CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with an enhanced side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in the Company's ongoing quarterly and an
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Therapies to Address the Underlying Cause of Cystic,Fibrosis; ... SOUTH PLAINFIELD, N.J., Aug. 20 New ... that the investigational oral drug,PTC124 demonstrates activity in ... with PTC124 results in statistically significant,improvements in the ...
... Oncothyreon Inc. (Nasdaq:,ONTY) (TSX: ONY) announced today that ... on August 14, 2008 indicating that Oncothyreon does ... The NASDAQ Global Market,because it does not meet ... (i) the market value of Oncothyreon,s common stock ...
... Crystal Research Associates, LLC,announced today that ... on Generex Biotechnology Corporation (Nasdaq: GNBT ... at http://www.crystalra.com ., Generex Biotechnology ... pharmaceutical company that aims to research, develop, ...
Cached Biology Technology:PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 2PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 3PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 4PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 5Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 2Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 3Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 3
(Date:4/22/2014)... of Yale researchers will lead a five-year, $3 million ... events is affecting the transport of dissolved organic matter ... say could alter the chemical composition and water quality ... funding from the National Science Foundation,s MacroSystems Biology program, ... the watershed, which begins in Canada and runs through ...
(Date:4/22/2014)... fist-like club of a mantis shrimp, a team of ... with University of Southern California and Purdue University, have ... more impact resistant and tougher than the standard used ... of this tiny crustacean, the more we realize its ... day," said David Kisailus, a Kavli Fellow of the ...
(Date:4/22/2014)... The Federation of American Societies for Experimental Biology (FASEB) ... (FY) 2013 highlighting how funding from the National Institutes ... DC, and Puerto Rico. "FASEB is pleased to make ... the significance of NIH to their state," said FASEB ... nation,s leading source for biomedical research funding, investing ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3
... of children with undiagnosed learning disorders, developmental deficits, and ... challenges, which are explored in detail in a reflective ... a peer-reviewed journal published by Mary Ann Liebert, Inc. ... ahead of print at www.liebertpub.com/gtmb ...
... been extinct for 65 million years, newly published data ... is providing invaluable insights into their paleobiology. Ammonites, shelled ... inhabited the oceans for nearly 350 million years. Specimens ... that covered North America during the Cretaceous Period demonstrate ...
... are investigating a potential new treatment for lung disease that ... is studying how statins, drugs which are commonly used to ... , There is currently no effective treatment for acute ... rates for those who become critically ill and suffer lung ...
Cached Biology News:Unexplained childhood disorders 2New discoveries in North America's Great Plains bring ammonites to life 2New discoveries in North America's Great Plains bring ammonites to life 3Queen's University Belfast lung injury study could save lives in critically ill 2